ArticleAmerican journal of translational research2025
Efficacy and safety of erector spinae plane block for the treatment of osteoporotic vertebral compressive fractures.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the efficacy and safety of erector spinae plane block (ESPB) for the treatment of osteoporotic vertebral compressive fractures (OVCF).
methodsA total of 120 OVCF patients, admitted between March 2022 and September 2022, were enrolled and assigned to either a control group or a research group (n=60 each) in this retrospective study. The control group received conventional analgesic treatment, while the research group was treated with ESPB. Data were collected at three time points: before surgery (T0), after four treatment sessions (T1), and prior to discharge (T2). Pain intensity was assessed using the Short-Form McGill Pain Questionnaire (SF-MPQ), which includes the Pain Rating Index (PRI), Visual Analogue Scale (VAS), and Present Pain Intensity (PPI). Inflammatory markers such as tumor necrosis factor-α (TNF-α), high-mobility group box-1 (HMGB-1), and high-sensitivity C-reactive protein (hs-CRP) were measured. Additional parameters included the number of intramuscular tramadol injections from days 4 to 7, sleep quality using the Pittsburgh Sleep Quality Index (PSQI), quality of life via the 16-item Assessment of Health-Related Quality of Life in Osteoporosis (ECOS-16), and treatment satisfaction.
resultsThe research group exhibited significant reductions in PRI, VAS, and PPI at T0, T1, and T2 compared to the control group (all P<0.05). At T1 and T2, pain scores in the research group were notably lower than those in the control group (all P<0.05). Two weeks post-treatment, levels of TNF-α, HMGB-1, and hs-CRP were significantly lower in the research group than in the control group and pre-treatment values (all P<0.05). Conversely, the ECOS-16 score was significantly higher in the research group (P<0.05). Furthermore, the research group required fewer intramuscular tramadol injections (days 4-7) and reported higher treatment satisfaction (both, P<0.05).
conclusionsESPB for OVCF patients demonstrated significant analgesic benefits, reducing pain, serum inflammatory markers, tramadol injections during days 4-7, and improving sleep quality, quality of life, and treatment satisfaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.